Up­dat­ed: ICER on Alzheimer's: lecanemab should be priced low­er than Aduhelm

Drug pric­ing watch­dog ICER said that the un­cer­tain­ty in the health ben­e­fits of two po­ten­tial Alzheimer’s drugs makes it chal­leng­ing to as­sess their fu­ture cost-ef­fec­tive­ness, ac­cord­ing to a draft re­port re­leased Thurs­day morn­ing.

The re­port eval­u­ates Bio­gen and Ei­sai’s lecanemab and Eli Lil­ly’s do­nanemab, both of which are amy­loid-clear­ing an­ti­body drugs due for FDA de­ci­sions in the com­ing weeks and months. The FDA’s dead­line for a de­ci­sion on lecanemab’s ac­cel­er­at­ed ap­proval is Jan. 6, while the dead­line for do­nanemab is es­ti­mat­ed to be in Feb­ru­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER